Two Decades of Advances in Preeclampsia Research: Molecular Mechanisms and Translational Studies

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2024 Aug 1

PMID 39087479

Authors

S Ananth Karumanchi

Affiliations

Soon will be listed here.

Citing Articles

Subcellular Localization Guides eNOS Function.

Villadangos L, Serrador J Int J Mol Sci. 2025; 25(24.

PMID: 39769167 PMC: 11678294. DOI: 10.3390/ijms252413402.

First-Trimester Preeclampsia-Induced Disturbance in Maternal Blood Serum Proteome: A Pilot Study.

Starodubtseva N, Tokareva A, Kononikhin A, Brzhozovskiy A, Bugrova A, Kukaev E Int J Mol Sci. 2024; 25(19).

PMID: 39408980 PMC: 11476624. DOI: 10.3390/ijms251910653.

The Hidden Relationship between Intestinal Microbiota and Immunological Modifications in Preeclampsia Pathogenesis.

Zambella E, Peruffo B, Guarano A, Inversetti A, Di Simone N Int J Mol Sci. 2024; 25(18).

PMID: 39337584 PMC: 11432041. DOI: 10.3390/ijms251810099.

References

Dupont V, Berg A, Yamashita M, Huang C, Covarrubias A, Ali S . Impaired renal reserve contributes to preeclampsia via the kynurenine and soluble fms-like tyrosine kinase 1 pathway. J Clin Invest. 2022; 132(20). PMC: 9566901. DOI: 10.1172/JCI158346. View

Burke S, Zsengeller Z, Khankin E, Lo A, Rajakumar A, DuPont J . Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. J Clin Invest. 2016; 126(7):2561-74. PMC: 4922717. DOI: 10.1172/JCI83918. View

Roberts J, Taylor R, Musci T, Rodgers G, Hubel C, McLaughlin M . Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989; 161(5):1200-4. DOI: 10.1016/0002-9378(89)90665-0. View

Thadhani R, Cerdeira A, Karumanchi S . Translation of mechanistic advances in preeclampsia to the clinic: Long and winding road. FASEB J. 2024; 38(3):e23441. DOI: 10.1096/fj.202301808R. View

Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi S . Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol. 2015; 27(3):903-13. PMC: 4769204. DOI: 10.1681/ASN.2015020157. View

Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N . Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003; 111(5):707-16. PMC: 151905. DOI: 10.1172/JCI17423. View

Fan X, Rai A, Kambham N, Sung J, Singh N, Petitt M . Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J Clin Invest. 2014; 124(11):4941-52. PMC: 4347223. DOI: 10.1172/JCI76864. View

Thadhani R, Lemoine E, Rana S, Costantine M, Calsavara V, Boggess K . Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. NEJM Evid. 2024; 1(12):EVIDoa2200161. DOI: 10.1056/EVIDoa2200161. View

McGinnis R, Steinthorsdottir V, Williams N, Thorleifsson G, Shooter S, Hjartardottir S . Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. Nat Genet. 2017; 49(8):1255-1260. DOI: 10.1038/ng.3895. View

10.

Levine R, Lam C, Qian C, Yu K, Maynard S, Sachs B . Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355(10):992-1005. DOI: 10.1056/NEJMoa055352. View

11.

Maynard S, Min J, Merchan J, Lim K, Li J, Mondal S . Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111(5):649-58. PMC: 151901. DOI: 10.1172/JCI17189. View

12.

Erez O, Romero R, Jung E, Chaemsaithong P, Bosco M, Suksai M . Preeclampsia and eclampsia: the conceptual evolution of a syndrome. Am J Obstet Gynecol. 2022; 226(2S):S786-S803. PMC: 8941666. DOI: 10.1016/j.ajog.2021.12.001. View

13.

Levine R, Maynard S, Qian C, Lim K, England L, Yu K . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7):672-83. DOI: 10.1056/NEJMoa031884. View

14.

Parchem J, Kanasaki K, Kanasaki M, Sugimoto H, Xie L, Hamano Y . Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice. J Clin Invest. 2018; 128(11):5008-5017. PMC: 6205389. DOI: 10.1172/JCI99026. View

15.

Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W . Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011; 124(8):940-50. DOI: 10.1161/CIRCULATIONAHA.111.034793. View

16.

Turanov A, Lo A, Hassler M, Makris A, Ashar-Patel A, Alterman J . RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat Biotechnol. 2018; . PMC: 6526074. DOI: 10.1038/nbt.4297. View

17.

Haase N, Foster D, Cunningham M, Bercher J, Nguyen T, Shulga-Morskaya S . RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models. J Clin Invest. 2020; 130(6):2928-2942. PMC: 7260005. DOI: 10.1172/JCI99417. View

18.

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff A, Sennstrom M . Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016; 374(1):13-22. DOI: 10.1056/NEJMoa1414838. View

19.

Kendall R, Thomas K . Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993; 90(22):10705-9. PMC: 47846. DOI: 10.1073/pnas.90.22.10705. View

20.

Zhou Y, Gormley M, Hunkapiller N, Kapidzic M, Stolyarov Y, Feng V . Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia. J Clin Invest. 2013; 123(7):2862-72. PMC: 3999620. DOI: 10.1172/JCI66966. View